Recruitment of 687 patients globally completed in fifteen months, ahead of schedule
FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study1, and to support global registrations
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (
